







































- patients with locally advanced bladder cancer. *Oncology* 2017;93:36-42.
108. Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, et al. Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer. *Cancer Res Treat* 2018;50:691-700.
  109. Camidge DR, Otterson GA, Clark JW, Ou SHI, Weiss J, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): updated safety and efficacy findings from a phase 1 trial. *J Clin Oncol* 2018;36:9062.
  110. Rau KM, Kang HY, Cha TL, Miller SA, Hung MC. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. *Endocr Relat Cancer* 2005;12:511-32.
  111. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, et al. Concordance among gene-expression-based predictors for breast cancer. *N Engl J Med* 2006;355:560-9.
  112. Harbeck N, Gnant M. Breast cancer. *Lancet* 2017;389:1134-50.
  113. Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: updated review. *Ochsner J* 2017;17:405-11.
  114. Sporn MB LS. Agents for chemoprevention and their mechanism of action. *Holland-Frei Cancer Medicine: BC Decker*; 2003.
  115. Godinho MF, Sieuwerts AM, Look MP, Meijer D, Foekens JA, et al. Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. *Br J Cancer* 2010;103:1284-91.
  116. Liu H, Wang G, Yang L, Qu J, Yang Z, et al. Knockdown of long non-coding RNA UCA1 increases the tamoxifen sensitivity of breast cancer cells through inhibition of Wnt/beta-catenin pathway. *PLoS One* 2016;11:e0168406.
  117. Feng Y, Hu X, Zhang Y, Zhang D, Li C, et al. Methods for the study of long noncoding RNA in cancer cell signaling. *Methods Mol Biol* 2014;1165:115-43.
  118. Arun G, Diermeier S, Akerman M, Chang KC, Wilkinson JE, et al. Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. *Genes Dev* 2016;30:34-51.
  119. Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res* 2013;73:1180-9.
  120. Yin DD, Liu ZJ, Zhang E, Kong R, Zhang ZH, et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. *Tumour Biol* 2015;36:4851-9.
  121. Marin-Bejar O, Marchese FP, Athie A, Sanchez Y, Gonzalez J, et al. Pint lincRNA connects the p53 pathway with epigenetic silencing by the Polycomb repressive complex 2. *Genome Biol* 2013;14:R104.
  122. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. *Mol Oncol* 2012;6:155-76.